Fundraising Fox

Calyxo

Pleasanton, US · Founded 2016 · Delaware corporation · 385 employees on LinkedIn · 5 known investors

Calyxo develops medical devices for kidney stone removal, specifically a minimally invasive CVAC (Cavitation-Enabled Ablation and Clearance) system that has been FDA-cleared. The company serves urologists and patients seeking routine, single-treatment kidney stone management.

HealthtechMedical Devices

Founders & leadership

CB
Chris BuchkoExecutive
DH
Douglas HughesExecutive
JS
Jee ShinExecutive
MK
Mark KiddExecutive
JC
Joe CataneseNamed on SEC filing

Board

RDRyan Drant
Ryan Drantin𝕏Board directorFounder and Managing Partner at Questa Capital
JG
Jacob GarfieldBoard director
RC
Robert Calvin GoforthBoard director
DA
Dave AmersonBoard director

Investors · 5

Questa CapitalSan Francisco · $15M – $40Mvia Ryan Drant · board
Ally Bridge GroupreportedNew York
Janus Henderson InvestorsreportedLondon

Also in the syndicate · 2

Avidity PartnersCRG

Reported raises · per SEC filings

Form D private placements

$156.1M disclosed across 9 of 10 rounds · 2016–2026

▶$40.1MraisedApr 2026 · 12 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Douglas HughesExecutive Officer, Director
  • Jee ShinExecutive Officer, Director
  • Joe CataneseExecutive Officer, Director
  • Jacob GarfieldDirector
  • Dave AmersonDirector
  • Ryan DrantDirector
  • Chris BuchkoExecutive Officer
  • Dana G. MeadDirector
Offering amount
$40.1M
Amount sold
$40.1M
First sale
Apr 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$28.3MraisedDec 2024 · 10 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Joe CataneseExecutive Officer, Director
  • Chris BuchkoExecutive Officer
  • Dave AmersonDirector
  • Douglas HughesExecutive Officer, Director
  • Ryan DrantDirector
  • Jee ShinExecutive Officer, Director
  • Jacob GarfieldDirector
Offering amount
$32M
Amount sold
$28.3M
First sale
Dec 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$50MraisedNov 2023 · 16 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Ryan DrantDirector
  • Douglas HughesExecutive Officer, Director
  • Jee ShinExecutive Officer, Director
  • Dave AmersonDirector
  • Joe CataneseExecutive Officer, Director
  • Chris BuchkoExecutive Officer
  • Jacob GarfieldDirector
Offering amount
$50M
Amount sold
$50M
First sale
Oct 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$22.7MraisedFeb 2022 · 18 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Douglas HughesExecutive Officer, Director
  • Joe CataneseExecutive Officer, Director
  • Jee ShinExecutive Officer, Director
  • Chris BuchkoExecutive Officer
  • Ryan DrantDirector
  • Dave AmersonDirector
Offering amount
$22.7M
Amount sold
$22.7M
First sale
Jan 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$12.9MraisedOct 2019 · 20 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Jee ShinExecutive Officer, Director
  • Ryan DrantDirector
  • Robert Calvin GoforthDirector
  • Beverly HussDirector
  • Douglas HughesDirector
Offering amount
$15.9M
Amount sold
$12.9M
First sale
Oct 2019
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$450KraisedMay 2019 · 17 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Jee ShinExecutive Officer, Director
  • Beverly HussDirector
  • Douglas HughesDirector
  • Robert Calvin GoforthDirector
Offering amount
$1M
Amount sold
$450K
First sale
Apr 2019
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.6MraisedAug 2018 · 50 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Douglas HughesDirector
  • Robert Calvin GoforthDirector
  • Jee ShinExecutive Officer, Director
Offering amount
$1.7M
Amount sold
$1.6M
First sale
Jun 2018
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$30KraisedSep 2017 · 2 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Jee ShinExecutive Officer, Director
  • Mark KiddExecutive Officer
  • Robert Calvin GoforthDirector
Offering amount
$150K
Amount sold
$30K
Minimum investment
$10K
First sale
Sep 2017
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Careers - Calyxocalyxoinc.com · May 2026Calyxo raises $40m to advance kidney stone removal systemfinance.yahoo.com · Apr 2026Calyxo Secures $40 Million Series F Financing as CVAC System Surpasses 40,000 Patients Treated for Kidney Stone Removalbusinesswire.com · Apr 2026Calyxo Secures $40M in Series F Fundingfinsmes.com · Apr 2026Sell or Invest in Calyxo Stock Pre-IPOnasdaqprivatemarket.com · Dec 2025Calyxo Raises $50M in Series D Fundingfinsmes.com · Dec 2023

Frequently asked questions

What does Calyxo do?
Calyxo develops medical devices for kidney stone removal, specifically a minimally invasive CVAC (Cavitation-Enabled Ablation and Clearance) system that has been FDA-cleared. The company serves urologists and patients seeking routine, single-treatment kidney stone management.
Who are Calyxo's investors?
Calyxo's investors include Questa Capital, Ally Bridge Group, Janus Henderson Investors.
How much funding has Calyxo raised?
Calyxo has disclosed $156.1M raised across 9 of its 10 known rounds.
Where is Calyxo headquartered?
Calyxo is headquartered in Pleasanton, US.